The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Daratumumab- versus isatuximab-based regimens in newly diagnosed multiple myeloma
Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Vienna, Austria, discusses a systematic review and meta-analysis comparing daratumumab- and isatuximab-based regimens in newly diagnosed multiple myeloma. He highlights broadly similar progression-free survival (PFS) and overall efficacy, with minor differences in response rates and grade 3 or higher infections, while emphasizing the heterogeneity of the available studies and the limitations of indirect comparisons. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
